INTRODUCTION
============

Autism spectrum disorder (ASD) is diagnosed clinically, based on the key symptoms including qualitative impairments in social communication and the presence of restricted and repetitive behaviors ([@B1]). However, the variability of the clinical phenotype of ASD is quite large and symptoms can manifest over a range of ages in childhood. Thus, ASD diagnosis can be challenging and is often not made until 3--5 years of age. For this reason, a physiologic ASD biomarker is highly desirable.

Several lines of evidence suggest that an impairment of GABAergic transmission may be critical in the pathophysiology of ASD (see [@B11] for a review). GABA plays a key role in regulating neuronal excitability via feedback and feed-forward inhibition ([@B53]; [@B47]; [@B32]; [@B26]). While in the mature brain GABA acts as an inhibitory neurotransmitter, during the embryonic and the perinatal period, GABA is excitatory ([@B10]). It is hypothesized that at least some forms of autism result from an imbalance between excitation and inhibition in local circuits involved in sensory, mnemonic, social, and emotional processes ([@B50]; [@B34]). [@B5], for instance, suggest that a dysfunction in the shift of GABA from excitation to inhibition may contribute to this imbalance.

Empirical support for the role of aberrant GABA signaling in the pathophysiology of ASD comes from both human and animal model research. A recent study conducted by [@B57] found that GABA had excitatory action in two animal models of ASD \[rats exposed to valproate in utero (VPA) and mice carrying the fragile X mutation (FRX)\]. Furthermore, maternal pretreatment with bumetanide, forcing the shift of GABA in the offspring from excitatory to inhibitory, resulted in the restoration of typical electrophysiological and behavioral phenotypes in affected animals ([@B57]).

Human studies have found reduced GABA receptor expression ([@B14],[@B17], [@B16]) as well as a 50% reduction in enzymes that synthesize GABA \[*glutamic acid decarboxylase* (GAD) 65 and 67; [@B15]; [@B60]\] in individuals with ASD. Furthermore, a recent study ([@B20]) identified significant reduction in the GABA MRS signal in the motor cortex of patients with ASD, and a marginally significant (*p* = 0.054) positive correlation between the GABA signal and age. Among the many roles of GABAergic circuits during development, one is lateral inhibition across neighboring minicolumns in the cortex. Consistent with an impairment in GABAergic transmission, postmortem studies have found a reduction in the horizontal spacing between minicolumns ([@B9]). These abnormalities in the GABA system may directly contribute to altered anatomical and functional connectivity, and suggest a mechanism underlying the neurological and behavioral phenotype of ASD ([@B6]).

In addition to and perhaps as a consequence of excitation/inhibition imbalance, recent studies in both human and animal models implicate synaptic plasticity mechanisms in the pathophysiology of ASD (see [@B45]). While most synaptic plasticity data in ASD are derived from *in vitro* rodent brain slice models, direct measures of circuit level plasticity in humans can be obtained by transcranial magnetic stimulation (TMS) paradigms ([@B61]; [@B24]; [@B56]; [@B27]). In TMS, the cortex is stimulated focally by small intracranial electrical currents that are generated by a powerful and fluctuating extracranial magnetic field ([@B2]; [@B29]; [@B23]). A number of experimental TMS measures of brain plasticity have been introduced, and provide the only noninvasive capacity to measure human phenomena that closely resemble long-term potentiation (LTP) and long-term depression (LTD). TMS is safe and well-tolerated, even in pediatric populations, if appropriately guidelines and recommendations are followed ([@B21]; [@B48]).

Single-pulse TMS combined with EMG, EEG, fMRI, or other brain imaging methods can be used to quantify cortical reactivity before and following a given intervention ([@B46]) providing an index of brain plasticity in response to said intervention. Recently, patterned bursting protocols have been developed that mimic paradigms used to assess synaptic plasticity in animal models ([@B24], [@B25]). Specifically, theta burst stimulation (TBS) involves application of three bursts of 50-Hz rTMS repeated every 200 ms either continuously for a total of 40 s or intermittently (every 8 s) for about 3 min. When applied to the motor cortex, continuous TBS (cTBS) and intermittent TBS (iTBS) result in depression and potentiation of cortical reactivity as indexed through suppression and facilitation of motor evoked potentials (MEPs), respectively ([@B24]). Results from animal and human studies indicate that TBS modulatory effects on cortical reactivity reflect synaptic plasticity mechanisms ([@B8]). Specifically, and relevant to the present experiment, published data suggest that cTBS leads to enhancement of GABAergic inhibition ([@B52]; [@B3]).

Notably, compared to other rTMS protocols, TBS has the advantage of lower stimulation intensities and shorter durations than conventional protocols making this protocol more suitable for use in clinical and pediatric populations. The safety and tolerability of this protocol has recently been evaluated and shown to be safe in healthy children and in children with Tourette Syndrome ([@B59]).

In a recent study ([@B42]) we used the cTBS paradigm in 20 adults with Asperger's syndrome (high functioning ASD), and found them to show greater and longer-lasting suppression of cortical reactivity in the motor cortex following cTBS as compared to age-, gender-, and IQ-matched controls. The latency to return to baseline following TBS was on average between 80 and 90 min in the ASD group compared to 25--30 min in the controls. This finding was confirmed in a separate cohort of 15 individuals ([@B42]). Interestingly, and consistent with other studies, there was no significant group difference in measures of basic excitability as assessed by resting and active motor threshold ([@B55]; [@B42]; [@B13]) or response to single pulse TMS ([@B42]). Thus, the excessive modulation of excitability in response to stimulation (a putative measure of plasticity) is not primarily attributable to differences in baseline excitability.

In the current study, we extended our age range to include data from 19 children and adolescents with high-functioning ASD (HF ASD) to explore the effect of development on the response to the cTBS paradigm. As the application of rTMS to the understanding and treatment of pediatric neurological and psychiatric disorders is an emerging field ([@B19]; [@B12]), this study additionally aimed to provide evidence for the safety and tolerability of TBS in HF children and adolescents with ASD.

MATERIALS AND METHODS {#s1}
=====================

PARTICIPANTS
------------

We studied 19 males with HF ASD, age 9--18 years (See **Table [1](#T1){ref-type="table"}** for demographic characteristics of the sample). All participants gave informed consent or assent, which was also obtained from a parent or guardian to participate in the study. The study was reviewed and approved by the institutional review board at Boston Children's Hospital. Participants were recruited through local community advertisement. All participants had IQ \> 80 based on the Weschler Abbreviated Scale of Intelligence (WASI). All met DSM-IV-TR criteria for Autism, Asperger's Syndrome or PDD-NOS, and met criteria for ASD on the Autism Diagnostic Observation Schedule, Module 4 (ADOS). Some participants also had comorbid symptoms including inattention, anxiety, irritability, and obsessive-compulsive behaviors (See **Table [1](#T1){ref-type="table"}**). All participants were given a comprehensive neurological exam by a board-certified pediatric neurologist (Alexander Rotenberg) to confirm normal gross motor and fine motor function. Lastly, all participants were screened following published recommendations ([@B49]) to ensure that they did not have any condition that would put them at greater risk of an adverse event related to TMS (e.g., a personal or immediate family history of epilepsy).

###### 

Sample characteristics.

  Participant number   Age         IQ           ADOS Score   Comorbid symptoms                         Neuroactive medications       Response to cTBS
  -------------------- ----------- ------------ ------------ ----------------------------------------- ----------------------------- ------------------
  1                    11          100          13           Anxiety                                   Citalopram                    Suppression
  2                    9           94           7            None                                      None                          Facilitation
  3                    12          86           10           Anxiety, Inattention                      Citalopram, atomoxetine       Suppression
  4                    9           87           9            Anxiety ADHD                              None                          Suppression
  5                    14          115          8            Anxiety, ADHD                             Citalopram, atomoxetine       Facilitation
  6                    14          99           9            None                                      None                          Facilitation
  7                    10          106          12           None                                      None                          Suppression
  8                    9           88           7            None                                      None                          Facilitation
  9                    10          89           10           ADHD                                      Buspirone                     Suppression
  10                   11          93           9            Obsessive-Compulsive Behaviors, Anxiety   Sertraline, citalopram        Facilitation
  11                   11          115          7            ADHD                                      Methylphenidate               Suppression
  12                   13          129          9            Inattention                               Atomoxetine                   Suppression
  13                   14          115          8            ADHD                                      Atomoxetine                   Suppression
  14                   10          102          7            Irritability                              Risperidone                   Suppression
  15                   11          103          14           Inattention                               Guanfacine, methylphenidate   Facilitation
  16                   13          102          7            ADHD                                      Methylphenidate               Facilitation
  17                   18          121          12           None                                      None                          Suppression
  18                   18          83           13           None                                      None                          Suppression
  19                   17          81           13           None                                      None                          Suppression
  **AVERAGE**          **12.26**   **100.42**   **9.58**                                                                             

STIMULATION AND RECORDING
-------------------------

To evaluate modulation of corticospinal excitability (a putative index of cortical plasticity mechanisms) and specifically GABAergic inhibition, cTBS was applied to the primary motor cortex. The cTBS paradigm used in the current study was identical to that described by [@B24] and applied in previous studies in our laboratory ([@B43], [@B42]). The protocol consisted of three pulses of 50 Hz stimulation repeated at 200-ms intervals for 40 s (for a total of 600 pulses) at an intensity of 80% of active motor threshold (AMT). Corticospinal excitability was assessed prior to and following cTBS by measuring peak-to-peak amplitude of MEPs induced in the contralateral first dorsal interosseus (FDI) muscle in response to single-pulse TMS. These single pulses were applied at a rate of approximately 0.1 Hz (a random jitter of ±1 s was introduced to avoid any train effects). Three batches of 10 MEPs were recorded prior to cTBS and used as a baseline. Beginning at 5 min following cTBS, batches of 10 MEPs were measured at periodic intervals (5, 10, 15, 20, 30, 40, 50, 60, 70, 80, 90, 105, and 120 min) until the MEPs returned to baseline levels to track changes in MEP amplitude over time. The participant was asked to remain relaxed during the entire study. Muscle activity was monitored throughout the session with EMG surface electrodes. TMS was only applied when the EMG signal indicated that the participant's FDI muscle was in a relaxed state. Any trials where the participant voluntarily contracted the muscle within 1000 ms of the TMS pulse were not included in the analysis.

To measure TMS induced MEPs, EMG surface electrodes were placed in a belly tendon montage over the FDI muscle of participants' right hands. Raw signals were amplified and bandpass-filtered between 20 and 2000 Hz. EMG signals were sampled at a rate of 5000 Hz. All stimulation (single-pulse TMS and TBS) was delivered using a hand-held 70 mm figure-of-eight coil attached to a Magstim Super Rapid stimulator (The MagStim Company Ltd., Whitland, UK). The coil was placed tangentially to the scalp with the handle pointing posteriorly. All stimulation was applied over the hand area of the left motor cortex and individually localized for each participant based on the optimal position for eliciting MEPs in the right FDI. The stimulation intensity for baseline and post-TBS single pulses was set at 120% of each individual's resting motor threshold (RMT) while the TBS itself was delivered at 80% of AMT. RMT and AMT were defined following recommendation from the International Federation of Clinical Neurophysiology. RMT was defined as the minimum single-pulse TMS intensity required to induce an MEP in the contralateral FDI of \>50 μV peak-to-peak amplitude on more than five out of ten consecutive trials while the target muscle was at rest. AMT was defined as the minimum single-pulse TMS intensity required to induce an MEP in the contralateral FDI of \>200 μV peak-to-peak amplitude on more than five out of ten consecutive trials while the target muscle was held at approximately 20% of the maximal contraction. To precisely target the stimulation site (primary motor cortex) and keep the brain target constant throughout the stimulation session, we used a frameless stereotactic neuronavigation system (Brainsight, Rogue Research Inc., Montreal, QC, Canada).

DATA ANALYSIS
-------------

Data were analyzed using MatLab version 8.1 and SPSS version 22. Data analysis followed the methods described and applied in previous studies in our laboratory ([@B43], [@B42]). Average MEP amplitude values were calculated at baseline prior to TBS and starting five minutes after TBS and continuing until the average amplitude returned to within the 95% confidence interval of the baseline amplitude and did not return to outside that interval on subsequent time-point measures. MEP amplitudes were standardized, forming a ratio of MEP amplitudes following TBS relative to average baseline MEP amplitude for each individual.

Cubic spline interpolation was used to create smooth curves through the data points. Spline interpolation is a piecewise continuous function defined by third-degree polynomials in the intervals of a limited range of known data points (in this case, the time-points at which MEP data were collected with batches of 10 single TMS pulses). The use of spline interpolation on TMS data has been validated ([@B7]) and used in previous studies to evaluate degree and duration of modulation of MEP amplitudes following cTBS ([@B18]). As an index of the duration of the TBS-induced modulation of cortico-spinal excitability, we defined, for each participant, the time-point ("time to baseline") at which post-cTBS MEP amplitude returned to the average MEP amplitude at baseline, i.e., the time-point at which the spline crossed the MEP threshold.

A natural log transformation was applied to the data prior to analysis as tests of normality indicated that the data was significantly different than normal. A Pearson product-moment correlation coefficient was calculated to assess the degree of relationship between age and duration of response to cTBS.

SIDE EFFECT MONITORING
----------------------

Immediately following the TMS session a side effects questionnaire was completed by the experimenter. Participants were asked to report whether they experienced any of the following side effects: headache, neck pain, scalp pain or irritation, difficulty hearing, thinking or concentrating, change in mood, or any other change or side effect they experienced. The experimenter also noted whether the participant experienced a syncopal event or seizure. The participant also received a call the day after the TMS session and was once again asked to report whether they experienced any of the above side effects or to report any other side effect they experienced after they left the hospital. If the participant reported any side effect either immediately following the stimulation or the following day, its severity and duration were documented.

RESULTS
=======

TMS SAFETY AND TOLERABILITY
---------------------------

All participants tolerated TBS and single-pulse stimulation without serious adverse event. One participant had a mild headache after stimulation that was alleviated with a single acetaminophen dose. Two participants had mild fatigue after the session that resolved the following day. No other adverse events were reported.

AGE-DEPENDENT RESPONSE TO cTBS
------------------------------

A Pearson product-moment correlation coefficient was calculated to test the hypothesis that a linear relationship existed between age and duration of response to cTBS. As described above, response to the cTBS protocol was defined as duration of effect as defined by the number of minutes following cTBS before the participant returned to baseline excitability levels ("time-to-baseline"; *M* = 46.3 min, SD = 29.3 min). The results of the analysis indicated that there was a significant positive linear relationship between age and duration of response \[*r*(17) = 0.660, *p* \< 0.01; **Figure [1](#F1){ref-type="fig"}**\].

![**Correlation between age and the natural log transformed "time to baseline" for each individual following cTBS.** Graph shows a significant positive relationship between duration of modulation and age.](fnhum-08-00627-g001){#F1}

In addition to the planned analyses, it was noted that unlike our previous study that included only adult participants, a third of the participants (7 out of 19; ages 9, 11, 13, and 14) had a paradoxical facilitation in response to the cTBS protocol (**Figure [2](#F2){ref-type="fig"}**). Additional analyses were conducted excluding the seven participants who facilitated and the significant positive correlation between age and duration of response remained \[*r*(10) = 0.62, *p* \< 0.05\] with a Mean duration of 49.2 min (SD = 33.8 min). The subgroup of participants who displayed the paradoxical facilitation response was not predicted by comorbid symptoms or medication (χ^2^ = 0.091, *p* = 0.76).

![**Degree of maximal suppression or facilitation following cTBS.** Values falling above zero indicate paradoxical facilitation in response to the typically suppressive cTBS protocol. Seven out of 20 participants in this study, ages 9, 11, 13, and 14 showed this paradoxical facilitation.](fnhum-08-00627-g002){#F2}

DISCUSSION
==========

As the application of rTMS protocols to children increases, it is critical to evaluate the safety and tolerability of this procedure in these vulnerable populations. In the current study, all participants tolerated the stimulation and reported only minor discomforts that resolved quickly following the procedures. These findings add to the literature suggesting that rTMS is safe and well tolerated in children and in individuals with ASD ([@B21]; [@B19]; [@B12]; [@B59]; [@B44]; [@B48]). Systematic monitoring and documentation of side effects is critical moving forward to ensure that both participants and investigators have an accurate sense of both the range and frequency of side effects of rTMS in clinical and pediatric populations.

Our findings are also the first step toward the study of the developmental regulation of the cTBS effect and reveal a positive linear relationship between age and duration of modulation of cTBS. Specifically we found that the older participants had a longer lasting response. On the surface this may appear counter intuitive if we consider that response to TBS has been used by our group and others to indicate degree of plasticity. One would imagine that younger children have a greater, not lesser, capacity for plasticity ([@B28]). However, cTBS is thought to model LTD-like plasticity ([@B25]) and is related to GABAergic inhibitory tone. Thus, perhaps LTD-like plasticity or GABAergic inhibition increases over development, especially during adolescence ([@B51]). As we did not perform iTBS, we cannot speak to the development of LTP-like plasticity in this sample, however, it would be important to evaluate this process as well. Additionally, the current study did not include a sham control condition or any other rTMS protocol, thus it is unclear whether the results are specific to the cTBS paradigm.

Recently, the molecular mechanisms underlying the changes in cortical excitability induced by cTBS have been studied using MRS ([@B52]). The findings reveal that the effects of cTBS are mediated by changes in the local activity of inhibitory interneuronal cortical pathways (as measured by changes in cortical GABA concentration in the primary sensorimotor cortex; [@B52]). Consistent with the idea that younger children have less inhibitory tone, studies using paired pulse measures of intracortical inhibition have found that children display decreased levels of suppression as compared to adolescents or adults ([@B58]). This study further claimed that reduced GABA mediated intracortical inhibition may facilitate excitatory (LTP-like) cortical plasticity and motor learning in children. Thus, the current results, although obtained from individuals with ASD, provide further evidence of increasing capacity for LTD-like suppression of cortical excitability across childhood.

Additionally, the finding that over one third of our sample had a paradoxical facilitatory response to cTBS supports the notion of GABAergic dysfunction in ASD. During typical development, GABA currents shift from excitatory to inhibitory through a maturation of chloride transport mechanisms and an age-dependent reduction of intracellular chloride concentration \[(Cl^-^~i~; [@B4])\]. However, a recent study finds that two ASD animal models (rodent valproate and fragile X models) show excitatory GABA activity well beyond the age where wild-type animals' GABA activity has shifted to inhibition ([@B57]). In these animals administration of a GABA agonist (isoguvacine) led to an *increase* in spike frequency in neurons recorded from hippocampal slices as compared to a decrease in wild-type animals. Additionally, the in utero administration of bumetanide, a chloride importer antagonist that reduces intracellular chloride accumulation thereby promoting the shift of GABA from excitation to inhibition, resulted in the restoration of typical electrophysiological and behavioral phenotypes in affected offspring ([@B57]). These preclinical data support the hypothesis that a dysfunction in this shift may contribute to the pathophysiology of ASD ([@B5]). Ben-Ari and colleagues have proposed that this dysfunction may be a result of increased intracellular (\[Cl^-^\]~i~) concentrations in individuals with ASD. This is further supported by a study reporting paradoxical *increases* in hyperactivity in six out of seven and aggression in seven out of seven children with ASD who were treated with diazepam ([@B35]). Furthermore, in a recent clinical trial where bumetanide, was given to children with ASD results showed improvement in ASD symptoms as measured by the Childhood Autism Rating Scale (CARS) and the Repetitive and Restricted Behavior Scale (RRB) as well as a reduction in aberrant behavior as measured by the Aberrant Behavior Checklist (ABC; [@B31]). Our findings suggest that one could do an analogous study in humans to explore whether bumetanide would normalize the cTBS modulation in those with a paradoxical facilitation and if this normalization corresponded to improved behavioral symptoms.

We recently suggested that the neurological and behavioral ASD phenotypes are associated with altered brain plasticity that can be measured noninvasively by TMS ([@B45]). As our data showing age-dependence of the cTBS response suggest, the timing of plastic brain changes may be important for optimal development of cortical circuitry. As ASD is a developmental disorder it would be critical to evaluate the developmental trajectory of abnormalities in a putative mechanism underlying the phenotype.

As the current study did not include healthy control participants or females, it is not clear whether the observed developmental trajectory shown by these males with ASD is similar to what may be obtained in neurotypical individuals or females with ASD. It is possible that variables such as head size or myelination could have led to the observed correlation with age. However, as reviewed above, multiple lines of evidence point toward aberrant GABAergic transmission in ASD. Thus, it will be important to evaluate these measures in a healthy developing population and female ASD population to compare the typical developmental trajectory to that shown in males with ASD. Additionally, follow-up translational studies, analogous to what has been done in animal models, directly testing the relationship between GABA receptor expression \[measured by \[^11^C\] FMZ PET ([@B36])\] or concentration \[measured by MRS ([@B37])\] and measures of cortical reactivity in humans with ASD are needed.

In the current study, we focused on primary motor cortex in the left hemisphere. Thus, it is unclear whether other cortical regions would show similar developmental trajectories or whether there would be a laterality effect in these individuals. The left primary motor cortex was chosen in this study for two reasons. First, MEPs are the standard index used to quantify the effect of TBS protocols. Other indices of cortical excitability outside the motor cortex (e.g., based on electroencephalographic measures) have not yet been well validated for this application. We chose the left hemisphere as it is typically the dominant hemisphere for both right- and left-handed individuals. Second, although motor abnormalities are not considered core symptoms of ASD, many studies have reported motor deficits in individuals with ASD, including alterations in motor milestone development ([@B54]), clumsiness, motor incoordination, disturbances in reach-to-grasp movement ([@B39]; [@B22]; [@B33]), deficits in gross and fine motor movement ([@B41]), and impaired postural control ([@B30]; [@B38]). It has also been suggested that these motor deficits may underlie the core deficits in ASD ([@B40]).

Our results support the safety and tolerability of TBS in the pediatric ASD populations. As we continue to enhance our understanding of the relationship between the response to cTBS with GABAergic inhibition and GABAergic dysfunction with ASD pathophysiology we suggest that cTBS may be a practical biomarker of GABAergic dysfunction in this population.
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